U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07265258) titled 'A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease' on Nov. 24.
Brief Summary: This is a multicenter, randomized, open-label, active-controlled Phase IV clinical trial in participants with active thyroid eye disease (TED). Approximately 92 eligible participants will be randomized to the teprotumumab N01 group and the intravenous glucocorticoid (IVGC) group in a 1:1 ratio on Day 1. The randomization stratification factor is diplopia at baseline (Gorman diplopia score >=1 vs. Gorman diplopia score = 0).
Study Start Date: Dec. 30
Study Type: INTERVENTIONAL
Condition:
Thyroid Eye Disease
Intervention:
BIOLOGICA...